STOCK TITAN

Aprea Therapeutics Inc - APRE STOCK NEWS

Welcome to our dedicated news page for Aprea Therapeutics (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aprea Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aprea Therapeutics's position in the market.

Rhea-AI Summary
Aprea Therapeutics announces two poster presentations at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Aprea is developing ATRN-119 for solid tumor indications and ATRN-1051, with an IND submission expected in Q4 2023. Oren Gilad, CEO, will attend the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
-
Rhea-AI Summary
Aprea Therapeutics announces positive preclinical data for ATRN-1051 in ovarian cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
-
Rhea-AI Summary
Aprea Therapeutics to present corporate overview at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
conferences
Rhea-AI Summary
Aprea Therapeutics appoints Dr. Jean-Pierre Bizzari to its Board of Directors and names Dr. Richard Peters as new Chairman of the Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Aprea Therapeutics, Inc. reported financial results for Q2 2023, with cash and cash equivalents of $27.7 million. The company continues to make progress in its ATR inhibitor program, with enrollment ongoing in the Phase 1/2a trial of ATRN-119. The company expects to report initial interim safety, tolerability, and pharmacokinetic data in Q4 2023. In the WEE1 inhibitor program, IND enabling studies with ATRN-1051 are underway, with an IND filing anticipated by the end of 2023. Gabriela Gruia, M.D., has been appointed to the Board of Directors. The company reported an operating loss of $3.7 million for Q2 2023, compared to $98.5 million for the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.2%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
Aprea Therapeutics Inc

Nasdaq:APRE

APRE Rankings

APRE Stock Data

31.77M
4.19M
11.67%
17.7%
1.95%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Doylestown

About APRE

annan naturvetenskaplig och teknisk forskning och utveckling